RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹2,575.70down ₹428.10 (14.25%)BSE ₹2,572.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,003.80.
30 Oct: open ₹2,812.00, high ₹2,849.60, low ₹2,513.50
52-week range of traded prices to 30 Oct 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,260 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.94
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.20
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.93%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 17.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,38,78323.6% delivered
RPG Life Sciences orders, deals and press releases
63 filed, newest first. Page 2 of 2.
Oct 2013
Jul 2013
Jun 2013
May 2013
Apr 2013
Feb 2013
Oct 2011
Jan 2011
Nov 2010
2 Nov · Business
Committee of Directors at its meeting held on November 01, 2010 has issued and allotted 28,391 equity shares of Rs.8/- each under the Employees Stock Option Scheme (ESOP Scheme) pursuant to exercise of equivalent number of stock options by employees.
Sep 2010
Aug 2009
3 Aug · Business
RPG Life Sciences is launching "Sirolimus", a Biotech product. Sirolimus is the 2nd Biotech immunosuppressant API of the Company. Sirolimus technology is developed end-to-end by the Company through an in house R&D effort
Mar 2009
30 Mar · Business
Committee of Directors at its meeting held on March 30, 2009 has allotted 15,00,000 convertible warrants to Petrochem International Limited and 6,38,000 convertible warrants to KEC Holdings Limited, both Promoter Group Companies, on preferential basis, convertible into equivalent number of equity shares of face value of Rs.8/- each at a premium of Rs. 15.70 per share, in one or more tranches, within 18 months from the date of allotment of the warrants.
Feb 2009
20 Feb · Business
Board of Directors of the Company on February 20, 2009 has approved the following: (1) Issue of 15,00,000 convertible warrants to Petrochem International Limited and 6,38,000 convertible warrants to KEC Holdings Limited, both Promoter Group Companies, on preferential basis, aggregating to 21,38,000 convertible warrants, convertible into equivalent number of equity shares of face value of Rs.8/- each at a premium on full payment, in one or more tranches, within 18 months from the date of allotment of the warrants, at a price to be determined in accordance with the Guidelines for Preferential Issues contained In Chapter XIII of the Securities and Exchange Board of India (Disclosure & Investor Protection) Guidelines, 2000, considering February 24, 2009 as the Relevant Date for this purpose. The aforesaid issue of convertible warrants to the Promoters is subject to the approval of the shareholders of the Company. (2) Conduct of postal ballot for seeking the approval of the shareholders or the Company for above preferential issue.